Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.
The site in California has a successful regulatory track record and includes single-use bioreactors and associated downstream capabilities, Lonza said. The site employs more than 100 staff who will have the chance to keep working for Lonza, it added.
By Michael Shields
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.